Items where Funder is Celgene International SA.

A24078

Royle, K-L orcid.org/0000-0003-0225-1199, Coulson, AB, Ramasamy, K et al. (26 more authors) (2022) Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial. BMJ Open, 12 (11). e063037. ISSN 2044-6055

A25447

Royle, K-L orcid.org/0000-0003-0225-1199, Coulson, AB, Ramasamy, K et al. (26 more authors) (2022) Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial. BMJ Open, 12 (11). e063037. ISSN 2044-6055

No Ext Ref

Royle, K-L orcid.org/0000-0003-0225-1199, Coulson, AB, Ramasamy, K et al. (26 more authors) (2022) Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial. BMJ Open, 12 (11). e063037. ISSN 2044-6055

RV-CL-MM-PI-13264

Royle, K-L orcid.org/0000-0003-0225-1199, Coulson, AB, Ramasamy, K et al. (26 more authors) (2022) Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial. BMJ Open, 12 (11). e063037. ISSN 2044-6055